UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, which builds AI infrastructure for commercial decision-making in pharma, has raised €2.5 million to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. The round was led by Moonfire, including investments from Entrepreneurs First, Transpose Platform and General Advance. “Today, I am pretty proud of our product but…
Pharosyn, a London-based AI startup that provides competitive intelligence platforms for the pharmaceutical industry, has raised €2.5 million in investment. The funding round, led by Moonfire, also saw participation from Entrepreneurs First, Transpose Platform and General Advance. Founders Stephen Cowley and Joshua Hampson, who previously worked in AI research and biochemistry, aim to develop a platform that helps pharmaceutical companies make better strategic decisions by utilizing custom AI infrastructure.
This infrastructure can be applied across various areas such as commercial strategy, portfolio strategy, business development and licensing, market research, forecasting, and competitive intelligence. The company's mission is to provide tailored strategic reports based on clinical, regulatory, and commercial data sources, ultimately helping organisations optimise resource allocation.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
